NASDAQ
CG Oncology, Inc. (NASDAQ: CGON - Get Free Report) shares reached a new 52-week high during trading on Friday. The company traded as high as $46.01 and last traded at $44.84, with a volume of 98696 sh...
IRVINE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladd...
- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical bi...
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.57 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.3 per share a year ago....
IRVINE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladd...
Shares of CG Oncology, Inc. (NASDAQ: CGON - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the thirteen research firms that are covering the company, Marketbeat Ratings ...
CG Oncology remains a compelling buy, driven by strong phase 3 data for its oncolytic virus therapy in bladder cancer. CGON's lead candidate, cretostimogene grenadenorepvec, achieved a 41.8% complete ...
Highly specialized biotech CG Oncology (CGON 7.13%) was the subject of a new research report Wednesday, and its bullish tone helped lift the company's share price. This improved by more than 7% on the...
CG Oncology, Inc. (CGON) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price in...
No price data available for this timeframe.